United States· US:0088-2102_83c11919-ca6d-49f5-8f9f-7b8405fcbaec
Priftin
A rifapentine product containing rifapentine, registered in United States by sanofi-aventis U.S. LLC. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rifapentine is registered in 3 of 19 countries.
Countries holding a registration under ATC J04AB05 (rifapentine), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Rifapentine · ATC J04AB05
3 / 19 countries
- Norwayprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RIFAPENTINE
- Manufacturer
- sanofi-aventis U.S. LLC
- Country
- United States (US)
- ATC code
- J04AB05
- ATC class
- Rifapentine
- Defined daily dose
- 0.11 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1100882102243 BLISTER PACK in 1 CARTON (0088-2102-24) / 8 TABLET, FILM COATED in 1 BLISTER PACK (0088-2102-01)
- ndc110088-2102-24
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
268 interactions on record for rifapentine.
Graded by severity as the source publishes them — 115 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifapentine · interactions on record
268 records
- 115 severe
- 148 moderate
- 5 minor
Most severe, free to view
- RolapitantA04AD14severe
- NaloxegolA06AH03severe
- NaldemedineA06AH05severe
- EliglustatA16AX10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rifapentine in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a55cf7aa-a2fa-44d5-b4fb-e4d5c1482ffc GET /v1/drugs/a55cf7aa-a2fa-44d5-b4fb-e4d5c1482ffc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "150",
"substance": "RIFAPENTINE",
"productndc": "0088-2102",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA021024",
"marketing_category": "NDA"
}See everything about rifapentine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.